---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022604"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:52:57.748068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M

## Summary
- Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.
- CyPath Lung testing revenue increased 122% YoY; test volumes up 97% in first nine months of 2025.
- Net loss $5.1M ($4.74 per share) compared to $2.0M loss ($4.84 per share) in Q3 2024, driven by change in fair value of warrants.
- Raised $10.4M gross proceeds from equity transactions; cash and equivalents increased to $7.7M from $1.1M at year-end 2024.
- Appointed Roberto Rios and John J. Oppenheimer to board; regained full Nasdaq compliance for listing of BIAF and BIAFW.

## SEC filing metadata
- accession: 0001493152-25-022604
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/0001493152-25-022604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022604
- JSON: https://secwatch.observer/filing/0001493152-25-022604.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.